Short Communication: Novel Di- and Triselenoesters as Effective Therapeutic Agents Inhibiting Multidrug Resistance Proteins in Breast Cancer Cells
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25179732 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Dominika Radomska und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Synthesis and Technology of Drugs, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Białystok, Medical University of Bialystok, Medical University of Silesia.
Abstract (Originalsprache)
Breast cancer has the highest incidence rate among all malignancies worldwide. Its high mortality is mainly related to the occurrence of multidrug resistance, which significantly limits therapeutic options. In this regard, there is an urgent need to develop compounds that would overcome this phenomenon. There are few reports in the literature that selenium compounds can modulate the activity of P-glycoprotein (MDR1). Therefore, we performed in silico studies and evaluated the effects of the novel selenoesters EDAG-1 and EDAG-8 on BCRP, MDR1, and MRP1 resistance proteins in MCF-7 and MDA-MB-231 breast cancer cells. The cytometric analysis showed that the tested compounds (especially EDAG-8) are inhibitors of BCRP, MDR1, and MRP1 efflux pumps (more potent than the reference compounds—novobiocin, verapamil, and MK-571). An in silico study correlates with these results, suggesting that the compound with the lowest binding energy to these transporters (EDAG-8) has a more favorable spatial structure affecting its anticancer activity, making it a promising candidate in the development of a novel anticancer agent for future breast cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Synthesis and Technology of Drugs, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland.
- Department of Organic Chemistry, Medical University of Silesia, Jagiellonska 4, 41-200 Sosnowiec, Poland.
- Instituto de Química Orgánica General (IQOG-CSIC), Consejo Superior de Investigaciones Científicas, Juan de la Cierva 3, 28006 Madrid, Spain.
ORCID-Profile: Dominika Radomska, Robert Czarnomysy, Krzysztof Marciniec, Enrique Domínguez-Álvarez, Krzysztof Bielawski
Förderung
- Medical University of Białystok
- Medical University of Bialystok
- Medical University of Silesia
- Wroclaw Centre for Networking and Super-computing
Zitieren
APA
Radomska, D., Czarnomysy, R., Marciniec, K., Nowakowska, J., Domínguez-Álvarez, E., & Bielawski, K. (2024). Short Communication: Novel Di- and Triselenoesters as Effective Therapeutic Agents Inhibiting Multidrug Resistance Proteins in Breast Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25179732
Vancouver
Radomska D, Czarnomysy R, Marciniec K, Nowakowska J, Domínguez-Álvarez E, Bielawski K. Short Communication: Novel Di- and Triselenoesters as Effective Therapeutic Agents Inhibiting Multidrug Resistance Proteins in Breast Cancer Cells. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25179732
BibTeX
@article{Radomska2024,
author = {Radomska, Dominika and Czarnomysy, Robert and Marciniec, Krzysztof and Nowakowska, Justyna and Domínguez-Álvarez, Enrique and Bielawski, Krzysztof},
title = {Short Communication: Novel Di- and Triselenoesters as Effective Therapeutic Agents Inhibiting Multidrug Resistance Proteins in Breast Cancer Cells},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25179732}
}
EUVIMED